ProCE Banner Activity

Expert Guidance on the Evolving Therapeutic Landscape for HER2-Positive Early-Stage Breast Cancer

Slideset Download
Review the latest clinical data and expert guidance on management of HER2-positive early-stage breast cancer, including how to assess risk and plan (neo)adjuvant therapy; treat lower- vs higher-risk disease; and optimally manage adverse events associated with HER2-targeted therapy.

Released: June 30, 2020

Expiration: June 29, 2021

Share

Faculty

Lee Schwartzberg

Lee Schwartzberg, MD

Professor of Medicine
Chief
Division of Hematology and Oncology
University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Puma Biotechnology, Inc.

Seagen

Faculty Disclosure

Primary Author

Lee Schwartzberg, MD

Professor of Medicine
Chief
Division of Hematology and Oncology
University of Tennessee Health Science Center
Memphis, Tennessee
Executive Director
West Cancer Center
Germantown, Tennessee